Lb Pharmaceuticals ratios data for the quarter ended Jun 2026. These financial ratios cover 5 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2024 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|
| Efficiency | |||||
| Assets AverageAssets Avg. | 316.84M | 353.21M | 377.59M | ||
| Invested CapitalInvested Cap. | -92.05M | 311.16M | 302.65M | 379.84M | 333.75M |
| Leverage & Solvency | |||||
| Debt Ratio | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Valuation | |||||
| Price to EarningsP/E | -25.78 | 13.06 | -37.11 | -18.04 | |
| Price to BookP/B | 0.30 | 0.59 | 1.87 | 2.80 | |
| Enterprise Value | -222.79M | -116.13M | 341.49M | 603.20M | |
| EV to EBIT | 62.65 | 10.12 | -17.92 | -11.69 | |
| EV to EBITDA | 62.65 | 10.12 | -17.92 | -11.69 | |
| Market Capitalization | 91.69M | 179.08M | 707.12M | 930.99M | |
| Price to FCFP/FCF | -27.18 | -9.87 | -30.31 | -24.51 | |
| EV to FCF | 66.05 | 6.40 | -14.64 | -15.88 | |
| EV to CFO | 66.05 | 6.41 | -14.66 | -16.03 | |
| Return Ratios | |||||
| Return on Capital Employed [ROCE]ROCE | -8.15% | -11.38% | -24.20% | ||
| Return on Invested Capital [ROIC]ROIC | -8.21% | -11.41% | -24.02% | ||
| Return on Assets [ROA]ROA | -7.96% | -11.03% | -22.69% |